Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARS: Lovastatin for Coronary Atherosclerosis Progression
NCT00116870Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 1985
- Primary completion
- Feb 1992
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronary artery disease (CAD) and atherosclerosis comparing Lovastatin with Placebo (2 arms). Primary endpoint: Change in Percent Diameter Stenosis at 24 months. Started Jun 1985; status: completed.
02
Drugs
lovastatin
03
Conditions
coronary artery disease (CAD)atherosclerosis
Beyond the preview
Go deeper on NCT00116870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00116870.